Current management of the amenorrhea-galactorrhea syndrome.
Management of the amenorrhea-galactorrhea syndrome has changed considerably in the last 5 years. Better understanding of the neuroendocrine physiology of the central nervous system in general, and of the hypothalamic-pituitary region in particular, have contributed significantly to our understanding of the pathophysiology of this syndrome. Greater awareness by physicians, improved neuroradiologic techniques, and the development of immunoassays for prolactin have markedly improved our diagnostic abilities. Many more patients are being diagnosed as having a pituitary tumor. The recent introduction of microneurosurgical techniques and the new medications (ergolines) are changing the treatment of this syndrome. Women in the childbearing age--who are affected most often--can expect successful treatment in the majority of cases with resumption of normal menstrual function and fertility. However, certain risks are still posed, particularly during pregnancy. In spite of improved diagnosis and treatment, the natural history of prolactin-secreting pituitary tumors and the long-range effects are still not fully appreciated. More experience in time will be needed before the indications for and the efficacy of various treatment regimens are fully known.
D000236:Adenoma / Q000097:blood / Q000150:complications; D000568:Amenorrhea / Q000097:blood / Q000150:complications / Q000503:physiopathology / Q000628:therapy*; D005260:Female; D005687:Galactorrhea / Q000150:complications / Q000503:physiopathology / Q000628:therapy*; D006801:Humans; D007031:Hypothalamus / Q000502:physiology; D007775:Lactation Disorders / Q000628:therapy*; D010062:Ovulation Induction; D010911:Pituitary Neoplasms / Q000150:complications; D011247:Pregnancy; D011248:Pregnancy Complications / Q000628:therapy; D011388:Prolactin / Q000097:blood / Q000502:physiology; D013577:Syndrome
D011388:Prolactin